oncollm
(2)
Triomics
Triomics builds oncology-specific AI infrastructure that turns messy, unstructured cancer patient records into structured, cited, actionable data. Its OncoLLM engine and workflow agents automate clinical trial matching, visit preparation, and cancer registry reporting for leading cancer centers, cutting manual chart review time while increasing trial enrollment. Founded in 2021 and headquartered in New York, the company is used by 4 of the top 10 U.S. cancer hospitals and raised a $22M Series B led by Battery Ventures in May 2026.
Sarim Khan
Sarim Khan is co-founder and CEO of Triomics, a New York-based startup building oncology-specific AI agents that read the thousands of pages inside a cancer patient's chart so that clinicians don't have to. A chemical engineer trained at IIT Roorkee with a brief stint researching polymer gels in brain tissue at MIT, he started Triomics in 2021 with college friend Hrituraj Singh, went through Y Combinator's W21 batch, and by mid-2026 had raised $22 million in Series B financing led by Battery Ventures and deployed the platform at Memorial Sloan Kettering, Yale Cancer Center, and four of the top ten U.S. News cancer hospitals.